Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma

I. Richter, J. Dvořák, M. Urbanec, A. Bluml, E. Čermáková, J. Bartoš, J. Petera,

. 2015 ; 19 (1) : 48-53. [pub] 20150326

Language English Country Poland

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc15031275

AIM OF THE STUDY: The aim of this retrospective study was to determine the prognostic impact of epidermal growth factor receptor (EGFR) expression changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. MATERIAL AND METHODS: Fifty patients with locally advanced rectal cancer were evaluated. All the patients were administered the total dose of 44 Gy. Capecitabine has been concomitantly administered in the dose 825 mg/m(2) in two daily oral administrations. Surgery was indicated 4-8 weeks from the chemoradiotherapy completion. Epidermal growth factor receptor expression in the pretreatment biopsies and in the resected specimens was assessed with immunohistochemistry. RESULTS: All of 50 patients received radiotherapy without interruption up to the total planned dose. In 30 patients sphincter-saving surgery was performed, 20 patients underwent amputation of the rectum. Downstaging was described in 30 patients. Four patients have had complete pathologic remission. Twenty-six patients have had partial remission, the disease was stable in 15 patients. Progression was reported in 5 patients. The median disease-free survival was 64.9 months, median overall survival was 76.4 months. Increased EGFR expression was found in 12 patients (26.1%). A statistically significantly shorter overall survival (p < 0.0001) and disease-free survival (p < 0.0001) was found in patients with increased expression of EGFR compared with patients where no increase in the expression of EGFR during neoadjuvant chemoradiotherapy was observed. CONCLUSIONS: The overexpression of EGFR during neoadjuvant chemoradiotherapy for locally advanced rectal adenokarcinoma associated with significant shorter overall survival and disease free survival.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15031275
003      
CZ-PrNML
005      
20210121105125.0
007      
ta
008      
151005s2015 pl f 000 0|eng||
009      
AR
024    7_
$a 10.5114/wo.2015.50013 $2 doi
035    __
$a (PubMed)26199571
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a pl
100    1_
$a Richter, Igor $u Department of Oncology, Regional Hospital Liberec, Liberec, Czech Republic.
245    14
$a The prognostic significance of tumor epidermal growth factor receptor (EGFR) expression change after neoadjuvant chemoradiation in patients with rectal adenocarcinoma / $c I. Richter, J. Dvořák, M. Urbanec, A. Bluml, E. Čermáková, J. Bartoš, J. Petera,
520    9_
$a AIM OF THE STUDY: The aim of this retrospective study was to determine the prognostic impact of epidermal growth factor receptor (EGFR) expression changes during neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. MATERIAL AND METHODS: Fifty patients with locally advanced rectal cancer were evaluated. All the patients were administered the total dose of 44 Gy. Capecitabine has been concomitantly administered in the dose 825 mg/m(2) in two daily oral administrations. Surgery was indicated 4-8 weeks from the chemoradiotherapy completion. Epidermal growth factor receptor expression in the pretreatment biopsies and in the resected specimens was assessed with immunohistochemistry. RESULTS: All of 50 patients received radiotherapy without interruption up to the total planned dose. In 30 patients sphincter-saving surgery was performed, 20 patients underwent amputation of the rectum. Downstaging was described in 30 patients. Four patients have had complete pathologic remission. Twenty-six patients have had partial remission, the disease was stable in 15 patients. Progression was reported in 5 patients. The median disease-free survival was 64.9 months, median overall survival was 76.4 months. Increased EGFR expression was found in 12 patients (26.1%). A statistically significantly shorter overall survival (p < 0.0001) and disease-free survival (p < 0.0001) was found in patients with increased expression of EGFR compared with patients where no increase in the expression of EGFR during neoadjuvant chemoradiotherapy was observed. CONCLUSIONS: The overexpression of EGFR during neoadjuvant chemoradiotherapy for locally advanced rectal adenokarcinoma associated with significant shorter overall survival and disease free survival.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Dvořák, Josef $u Department of Oncology and Radiotherapy, Charles University, Medical School and Teaching Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Urbanec, Marek $u Department of Pathology, Ceska Lipa Hospital, Ceska Lipa, Czech Republic.
700    1_
$a Bluml, Antonin $u Department of Medical Biophysics, Charles University, Medical School and Teaching Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Čermáková, Eva $u Department of Medical Biophysics, Charles University, Medical School and Teaching Hospital, Hradec Kralove, Czech Republic.
700    1_
$a Bartoš, Jiří $u Department of Oncology, Regional Hospital Liberec, Liberec, Czech Republic.
700    1_
$a Petera, Jiří $u Department of Oncology and Radiotherapy, Charles University, Medical School and Teaching Hospital, Hradec Kralove, Czech Republic.
773    0_
$w MED00165426 $t Contemporary oncology (Poznań, Poland) $x 1428-2526 $g Roč. 19, č. 1 (2015), s. 48-53
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26199571 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20151005 $b ABA008
991    __
$a 20210121105123 $b ABA008
999    __
$a ind $b bmc $g 1092156 $s 914399
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2015 $b 19 $c 1 $d 48-53 $e 20150326 $i 1428-2526 $m Współczesna Onkologia $n Współcz. Onkol. $x MED00165426
LZP    __
$a Pubmed-20151005

Find record

Citation metrics

Archiving options